Ocrelizumab (Ocrevus) - early primary progressive multiple sclerosis (PPMS) 1 Published 13 January 2020 1 SMC2223 ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®) Roche Products Ltd 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the orphan medicine process ocrelizumab (Ocrevus ® ) is accepted for use within NHSScotland. Indication under review: for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. In a randomised, double-blind, phase III study, the risk of disability progression was significantly reduced in patients who received ocrelizumab compared with placebo

Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above

Cognitive rehabilitation for attention and memory in people with multiple sclerosis: a randomized controlled trial (CRAMMS) Cognitive Rehabilitation for Attention and Memory in People With Multiple Sclerosis: A Randomized Controlled Trial (CRAMMS) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions , 269215519890378 2019 Nov 26 [Online ahead of print] Cognitive Rehabilitation for Attention and Memory in People With Multiple Sclerosis: A Randomized Controlled Trial (CRAMMS) , , , , , , , , , Collaborators, Affiliations Expand Collaborators CRAMMS Trial Collaborative

Cladribine for treating relapsing–remitting multiple sclerosis Cladribine for treating relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 19 December 2019 www.nice.org.uk/guidance/ta616 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration (...) to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cladribine for treating relapsing–remitting multiple sclerosis (TA616) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 Information about cladribine 6 Marketing authorisation indication 6 Dosage

Disease modifying treatments for relapsing remitting multiple sclerosis. A health economic evaluation Disease modifying treatments for relapsing remitting multiple sclerosis - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Disease modifying treatments for relapsing remitting multiple sclerosis Order Download: Key message The Norwegian (...) Institute of Public health has previously assessed the efficacy, safety and cost effectiveness of drugs for relapsing remitting multiple sclerosis. In this report, three new drugs (cladribine, ocrelizumab and rituximab) are included. Effectiveness, safety and legal aspects are reported in a separate publication, as is ethical considerations. This report assesses the included drugs in light of the Norwegian priority setting criteria (benefit, resource use and disease severity). Relapsing remitting

Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab. A health technology assessment. - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Disease-modifying treatments for relapsing remitting multiple sclerosis (...) , including rituximab. A health technology assessment. Order Download: Key message We have systematically collected and reviewed the evidence for clinical effectiveness and general safety issues for disease modifying treatments for relapsing remitting multiple sclerosis, synthesised evidence from randomised controlled trials and non-randomised registry-based studies using network meta-regression, and carefully interpreted the findings. We included rituximab in our analysis as it is used off-label

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. The RADIANCE (...) phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis.We did a 24-month, multicentre, double-blind, double-dummy phase 3 trial in participants with relapsing multiple sclerosis at 147 medical centres and clinical practices in 21 countries. Participants were aged 18-55 years, had multiple sclerosis according to 2010 McDonald criteria, a relapsing clinical course, brain MRI lesions consistent with multiple

Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding to high efficacy disease modifying therapies SHTG Advice | 1 SHTG Advice Number 07 October 2019 In response to an enquiry from the Strategic Planning and Clinical Priorities Team, Planning and Quality Division, Scottish Government Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding (...) to high-efficacy disease modifying therapies Advice for NHSScotland Where patients understand and are willing to accept the demands, risks and uncertainties of treatment, autologous haematopoietic stem cell transplant (AHSCT) should be considered as a treatment option for patients with relapsing-remitting multiple sclerosis (RRMS) who have evidence of significant inflammatory disease activity that has not responded to adequate treatment with licensed high-efficacy disease modifying therapies (DMTs

Palliative care interventions for people with multiple sclerosis. People with multiple sclerosis (MS) have complex symptoms and different types of needs. These demands include how to manage the burden of physical disability as well as how to organise daily life, restructure social roles in the family and at work, preserve personal identity and community roles, keep self-sufficiency in personal care, and how to be part of an integrated care network. Palliative care teams are trained to keep open (...) with it and their families.To assess the effects (benefits and harms) of palliative care interventions compared to usual care for people with any form of multiple sclerosis: relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS) We also aimed to compare the effects of different palliative care interventions.On 31 October 2018, we conducted a literature search in the specialised register of the Cochrane MS and Rare Diseases of the Central Nervous

Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome: A Review of Clinical Effectiveness and Guidelines Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome: A Review of Clinical Effectiveness and Guidelines Minocycline for Relapsing-Remitting (...) Multiple Sclerosis and Clinically Isolated Syndrome: A Review of Clinical Effectiveness and Guidelines Last updated: September 16, 2019 Project Number: RC1183-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of minocycline for relapsing-remitting multiple sclerosis? What is the clinical effectiveness of minocycline for clinically isolated syndrome? What are the evidence-based guidelines regarding

Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines | CADTH.ca Find the information you need Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines Last updated: September 26, 2019 Project Number (...) : RC1190-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding switching to a second-line therapy in patients with relapsing-remitting multiple sclerosis? Key Message One evidence-based guideline was identified with one strong recommendation regarding switching from an interferon or glatiramer acetate to a second-line therapy in patients with relapsing-remitting multiple sclerosis and evidence

Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87 1 Translation of addendum A19-42 Fingolimod (multiple Sklerose bei Kindern und Jugendlichen) – Addendum zum Auftrag A18-87 (Version 1.0; Status: 28 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 May 2019 1.0 Commission: A19-42 Version: Status (...) : IQWiG Reports – Commission No. A19-42 Fingolimod (multiple sclerosis in children and adolescents) – Addendum to Commission A18-87 1 Addendum A19-42 Version 1.0 Fingolimod – Addendum to Commission A18-87 28 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Fingolimod (multiple sclerosis in children and adolescents) – Addendum to Commission A18-87 Commissioning agency: Federal Joint

Vaccine-preventable Infections and Immunization in Multiple Sclerosis 1 Practice guideline update: Vaccine-preventable infections and immunization in multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Mauricio F. Farez, MD, MPH, 1 Jorge Correale, MD, 1,2 Melissa J. Armstrong, MD, MSc, 3 Alexander Rae-Grant, MD, 4 David Gloss, MD, 5 Diane Donley, MD, 6 Yolanda Holler-Managan, MD, 7 Norman J. Kachuck, MD, 8 (...) . Department of Pediatrics, Neurology Division, Loma Linda University Health Care, CA 13. American Academy of Neurology, Minneapolis, MN 14. US Centers for Disease Control and Prevention, Atlanta, GA 15. Department of Neurology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA Address correspondence and reprint requests to American Academy of Neurology: guidelines@aan.com This practice guideline was endorsed by the Multiple Sclerosis Association of America on January 11, 2019

Long-term disability progression of pediatric-onset multiple sclerosis To evaluate long-term disability progression in pediatric-onset multiple sclerosis (POMS) and compare to adult-onset multiple sclerosis (AOMS).This was a retrospective cohort study using prospectively collected clinical information from the Swedish MS Registry. Clinical features were compared and Kaplan-Meier and Cox proportional hazards regression were used to assess the risk of reaching sustained Expanded Disability Status (...) Scale (EDSS) 3, 4, and 6 in POMS (multiple sclerosis [MS] onset <18 years) and AOMS (MS onset ≥18 years).A total of 12,482 persons were included; 549 (4.4%) were classified as POMS. The POMS cohort took longer to reach all 3 disability milestones from their MS onset, but did so at a younger age than the AOMS cohort. Primary progressive course (hazard ratio [HR] 4.63; 95% confidence interval [CI] 1.46-14.7), higher relapse rate in the first 5 years of disease (HR 5.35; 95% CI 3.37-8.49), and complete

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo.In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose (...) with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo. There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose. Longer and larger trials are required to determine the effect and risks of evobrutinib in patients with multiple sclerosis. (Funded

Ocrelizumab for treating primary progressive multiple sclerosis Ocrelizumab for treating primary Ocrelizumab for treating primary progressiv progressive multiple sclerosis e multiple sclerosis T echnology appraisal guidance Published: 12 June 2019 www.nice.org.uk/guidance/ta585 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ocrelizumab for treating primary progressive multiple sclerosis (TA585) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about

Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis Published 10 June 2019 1 Product update SMC2154 fingolimod 0.25mg, 0.5mg hard capsules (Gilenya®) Novartis Pharmaceuticals UK Ltd 5 April 2019 (Issued 10 May 2019) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated (...) submission fingolimod (Gilenya®) is accepted for use within NHSScotland. Indication under review: as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of patients aged 10 to <18 years: - Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy. or - Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses

Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis. Multiple sclerosis (MS) is a leading cause of neurological disability in young adults. The most widely accepted hypothesis regarding its pathogenesis is that it is an immune-mediated disease. It has been hypothesised that intraluminal defects, compression, or hypoplasia in the internal jugular or azygos veins may be important factors in the pathogenesis (...) . This is an update of a review first published in 2012.To assess the benefit and safety of venous PTA in people with MS and CCSVI.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group's Specialised Register up to 30 August 2018, CENTRAL (in the Cochrane Library 2018, issue 8), MEDLINE up to 30 August 2018, Embase up to 30 August 2018, metaRegister of Controlled Trials, ClinicalTrials.gov., the Australian New Zealand Clinical Trials Registry, and the World Health

Siponimod (Mayzent) - To treat adults with relapsing forms of multiple sclerosis Drug Approval Package: Mayzent (siponimod) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Mayzent (siponimod) Company: Novartis Pharmaceuticals Corporation Application Number: 209884 Approval Date: 03/26/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Cladribin (multiple Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-62 (...) Cladribine (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-62 Version 1.0 Cladribine (multiple sclerosis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cladribine (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30